J
Jalila Adnane
Researcher at University of South Florida
Publications - 13
Citations - 1059
Jalila Adnane is an academic researcher from University of South Florida. The author has contributed to research in topics: RHOA & Transgene. The author has an hindex of 9, co-authored 13 publications receiving 1034 citations.
Papers
More filters
Journal ArticleDOI
Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein.
James Turkson,Tammy Bowman,Jalila Adnane,Yi Zhang,Julie Y. Djeu,Madhavi Sekharam,David A. Frank,Lawrence B. Holzman,Jie Wu,Said M. Sebti,Richard Jove +10 more
TL;DR: It is demonstrated that Ras- and Rac1-mediated p38 and JNK signals are required for Stat3 transcriptional activity induced by the Src oncoprotein, delineating a network of tyrosine and serine/threonine kinase signaling pathways that converge on Stat3 in the context of oncogenesis.
Journal ArticleDOI
Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice.
TL;DR: RhoB is shown to be a potent suppressor of transformation and human tumor growth in nude mice and that RhoB-F is not a target for farnesyltransferase inhibitors.
Journal ArticleDOI
p21 WAF1/CIP1 Is Upregulated by the Geranylgeranyltransferase I Inhibitor GGTI-298 through a Transforming Growth Factor β- and Sp1-Responsive Element: Involvement of the Small GTPase RhoA
TL;DR: GGTI-298-mediated upregulation of p21 WAF1/CIP1 involves both an increase in the amount of DNA-bound Sp1-Sp3 and enhancement of Sp1 transcriptional activity.
Journal Article
Suppression of rho B expression in invasive carcinoma from head and neck cancer patients.
TL;DR: The results of this study give additional support to the notion that RhoB may play a tumor suppressive role in squamous cell carcinomas of the head and neck, and argue against inhibition of RHoB farnesylation as a mediator offarnesyltransferase inhibitors' antitumor activity.
Journal ArticleDOI
Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model.
Jalila Adnane,Rosalind J. Jackson,Santo V. Nicosia,Alan B. Cantor,W. Jack Pledger,Saïd M. Sebti +5 more
TL;DR: Results show that tumor onset in MMTV/v-Ha-ras mice is p2l-dependent with loss of p2L associated with earlier tumor appearance and increased tumor multiplicity and aggressiveness, suggesting that loss ofp21 is critical in early but not late eventsof Ras oncogenesis.